Avanos Medical (NYSE:AVNS) Reaches New 1-Year Low – What’s Next?

Shares of Avanos Medical, Inc. (NYSE:AVNS) reached a new 52-week low on Wednesday . The stock traded as low as $13.64 and last traded at $15.84, with a volume of 7687 shares traded. The stock had previously closed at $15.56.

Wall Street Analyst Weigh In

Separately, StockNews.com cut Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 3rd.

Avanos Medical Stock Up 4.9 %

The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46. The company has a market cap of $750.11 million, a P/E ratio of 47.59 and a beta of 0.98. The stock has a 50-day moving average of $16.15 and a 200 day moving average of $19.73.

Avanos Medical (NYSE:AVNS) last issued its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.40 by $0.03. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. Research analysts anticipate that Avanos Medical, Inc. will post 1.32 earnings per share for the current year.

Institutional Trading of Avanos Medical

Large investors have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. grew its holdings in shares of Avanos Medical by 27.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company’s stock worth $47,941,000 after purchasing an additional 644,267 shares during the last quarter. Tributary Capital Management LLC raised its position in shares of Avanos Medical by 38.1% during the fourth quarter. Tributary Capital Management LLC now owns 893,008 shares of the company’s stock worth $14,217,000 after purchasing an additional 246,379 shares during the period. Brown Advisory Inc. raised its position in Avanos Medical by 12.0% in the 4th quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company’s stock valued at $30,329,000 after buying an additional 204,218 shares during the last quarter. D. E. Shaw & Co. Inc. raised its position in Avanos Medical by 43.1% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company’s stock valued at $7,874,000 after buying an additional 148,902 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Avanos Medical by 189.8% in the 4th quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company’s stock valued at $3,210,000 after purchasing an additional 132,063 shares during the period. 95.17% of the stock is owned by institutional investors and hedge funds.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.